ArticleBMC cancer2025
Transcriptomic profiles of endocrine-resistant breast cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.Drug delivery · 2026Review
- Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations.NPJ breast cancer · 2026Article
- How fasting boosts breast cancer therapy.Nature · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe majority of breast cancer patients have tumors expressing estrogen receptor α (ER) and are treated with adjuvant endocrine therapy. However, nearly one-third relapse, most with retained ER expression.
methodsThis study investigated patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer. Patients with ER-positive relapses within five years of ongoing endocrine therapy were defined as endocrine-resistant (N = 69). Patients with no disease progression after 10 years were defined as endocrine-sensitive (N = 77). RNA was extracted from archived tumor blocks, followed by gene expression analysis.
resultsSignificant differences were observed with higher tumor grades, intrinsic subtype risk scores, and upregulated cell-cycle gene sets in resistant compared to sensitive patients' primary tumors. Metabolism-associated gene sets were upregulated, and estrogen-response gene sets downregulated in resistant patients' relapse compared to primary tumors.
conclusionsThis study highlights gene sets associated with endocrine resistance and identifies transcriptomic and clinicopathological profiles that may serve as potential prognostic markers for therapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.